Investigational drug · Phase 2
BL1107
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Dry Eye Disease, Glaucoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
2
Any phase or sponsor naming "BL1107"
First trial start
2025
Oct 24, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BL1107", any sponsor or status.
Conditions studied
As listed on its trial records.
- Dry Eye Disease
- Glaucoma
Approved drugs for the same conditions: Glaucoma · Dry eye disease · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "BL1107" as an intervention, largest first.
- Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular HypertensionPivotal-lookingCompleted
Bausch & Lomb IncorporatedIndustry
NCT07168902 · 252 participants · Start Oct 24, 2025 · Primary completion May 18, 2026
Drug: BL1107 Low dose; BL1107 High dose and 1 more · For: Glaucoma
Sites: Glendale, California; Newport Beach, California; Pasadena, California · 14 sites in all
Bausch & Lomb IncorporatedIndustry
NCT07778888 · 20 participants (planned) · Start Oct 19, 2026 · Primary completion Feb 2027
Drug: BL1107 · For: Dry Eye Disease
Sites: Newport Beach, California
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Dry Eye Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.